- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Crohn disease (CD)
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 228KB)
Upadacitinib – July 2023
Upadacitinib: Tablet 15 mg, Tablet 30 mg, Tablet 45 mg; Rinvoq®
Last updated
27 October 2023